NCT00989586 2017-02-06Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaOhio State University Comprehensive Cancer CenterPhase 1/2 Completed35 enrolled 11 charts